Page 770 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

754 Index

Molecular genetics, hematology (Continued) FAB classi cation, 476, 477t distribution, 165–166
quantitative PCR (Q-PCR), 657 idiopathic cytopenia o undetermined signi - granulation, 168–169, 170t

real-time PCR (R -PCR), 657 cance (ICUS), 480–481 maturation, 165, 165
single nucleotide polymorphisms (SNPs), incidence, 482 maturational characteristics, 165, 166, 166–169,
655, 655b pathophysiology 167t
Southern blot technique, 660–661, 662, 663 cell line abnormalities, 478 metamyelocyte, 167–168, 168

targeted sequencing, 664 cellular abnormalities, 478 myeloblast, 166, 167
Monitoring monoclonal antibody therapy, 637–638 chromosomal abnormalities, 477–478 myelocytes, 167, 168
Monoblasts, 97 clinical signs and symptoms, 478, 482 promyelocyte, 166–167, 168
Monoclonal antibodies (MAbs), 199–200, 621 epidemiology, 477 mature orms, 168

immunophenotyping, 403, 403t etiology, 476–477 production, 164–165
lymphoid re ractory anemia (RA), 480 New oral anticoagulants (NOAs), 540
B cell markers, 403, 404 re ractory anemia with excess blasts characteristics, 576, 576t
B-lineage markers, 403 (RAEB-1 and RAEB-2), 480 laboratory assays, 576–577, 577t

-lineage markers, 403 re ractory anemia with ring sideroblasts vs. war arin, 576
sur ace membrane markers, 403 (RARSs), 480, 480 Next generation sequencing (NGS), 384, 653, 664
Monoclonal antibody (MAb) testing, 196 treatment strategies, 481–482 cost-ef ective, 662
Monoclonal B-cell lymphocytosis (MLD), 422 WHO classi cation, 476, 477t data analysis, 663–664

Monocytes, 97, 98 Myelodysplastic syndromes/ myeloproli erative generalized overview, 662, 663
acute in ammatory response, 174–175 neoplasms (MDS/MPN ), 482, 482b Illumina, 663
cellular immunity, 180 Myelogenous leukemia, 373 Ion orrent PGM One ouch system, 663
characteristics, 172t Myeloid, 165 sequencing and imaging, 663

development, 169–170 Myelokathexis, 338 template preparation, 663
unctions, 170–171 Myelomas, 372 Niemann-Pick disease, 345
li e span Myeloperoxidase (MP), 690, 690 NK cells (see Natural killer (NK) cells)
circulatory phase, 172 Myeloperoxidase (MPO) de ciency, 340t, 344 Nomenclature, cell lines o , 96t

specialized unctions, 180 Myeloproli erative disorders, 518–519 Non-hodgkin lymphomas (NHL), 429
tissue phase, 172–173 Myeloproli erative neoplasm, unclassi able in children, 428
maturation, 171, 172 (MPN -U), 468 dif use large B-cell lymphoma (DLBCL), 431
monoblast, 172 Myeloproli erative neoplasms (MPNs), 482, 482b ollicular lymphoma (FL), 429, 429

morphological appearance, 589 categories o , 450, 450b lymphoplasmacytic lymphoma, 430–431
morphological characteristics, 172 chronic myelomonocytic leukemia (CMML) mantle cell lymphoma (MCL), 429–430
movement, 177 atypical chronic myeloid leukemia, 484 marginal zone B-cell lymphoma, 430
production, 170 characteristics o , 483b not otherwise speci ed (NOS), 431

role o , 174 cytochemical staining, 484b Nonhistones, 63
specialized unctions, 180 juvenile myelomonocytic leukemia, 484 Nonimmune heparin-induced thrombocytopenia,
Monocytic leukemias, 373 laboratory data, 483, 483 511
Monocytoid, 196 pathophysiology, 483 Nonmalignant lymphocytic disorders

Mononuclear phagocyte system, 91, 169, 171, classi cation, 468, 476, 482b acquired immunode ciency syndrome (HIV/
179–180, 496 clinical signs and symptoms, 482 AIDS)
Mononuclear phagocytes etiology, 482 clinical signs and symptoms, 363–365, 364
macrophages, 589 hemostasis and coagulation disorders, 450–451 disease progression, 365

monocytes, 589 incidence, 482 epidemiology, 363
polymorphonuclear segmented neutrophils pathophysiology, 482 etiology, 33
(PMNs), 589–590 prognosis and treatment, 451 HIV virus, 362, 363
Monosodium urate (MSU) crystals, 606 relationship o , 450, 451t laboratory data, 365

Monospot test, 685 MYH9-related thrombocytopenia syndromes, serological markers, 365–366
Mott cells/grape, 203, 203 515, 515 cytomegalovirus in ection
Moyamoya disease, 506 Myosin, 62 clinical signs and symptoms, 360
MPNs (see Myeloproli erative neoplasms) epidemiology, 359–360

MPV nomogram, 631 N etiology, 359
MSDS (see Material sa ety data sheet) Näive B cells, 417 laboratory data, 360
Mucopolysaccharidosis, 346 Naphthol as-D chloroacetate esterase, 514, 514-515 in ectious lymphocytosis, 361–362
Mucosa-associated lymphoid tissue (MAL ), 426 Natural anticoagulant systems, 541 in ectious mononucleosis

Multiple myeloma (MM) (see also Plasma cell) Natural killer (NK) cells, 198–199 characteristic antibody ormation, 359, 359t
clinical signs and symptoms, 435, 435 Necrosis, 62 classic Downey classi cation o , 358, 358t
emerging therapies, 439, 440b Neonatal autoimmune thrombocytopenia, 510 clinical signs and symptoms, 357–358
epidemiology, 434 Neonatal screening programs, 46 EBV, 356–357, 357, 359, 359

etiology, 434–435 Neoplasms, 372 epidemiology, 356–357, 358
laboratory data, 435–438, 436t–437t, 438, 439 Nephritis, acute, 366 etiology, 356, 357
treatment, 438 Neuroacanthocytosis (NA), 299 laboratory data, 358–359, 358t, 359, 359t
Multipotential hematopoietic stem cell, 89 Neutropenia reactive lymphocytosis, 361–362

Multipotential stem cells, 91 causes, 338 systemic lupus erythematosus
Myeloblasts, 97, 165, 166 chronic benign neutropenia, 339 antibody tests, 366–367
Myelocytes, 165, 166 cyclic neutropenia, 338 etiology, signs, and symptoms, 366
Myelodysplastic syndromes (MDS), 482, 482b Neutrophil extracellular traps (NE s), 180 laboratory data, 366

chronic myelomonocytic leukemia (CMML) Neutrophilic hypersegmentation index, 217 LE cell preparation, 366
atypical chronic myeloid leukemia, 484 Neutrophils lymphocyte subsets, 367
characteristics o , 483b adherence and migration toxoplasmosis
cytochemical staining, 484b capture (tethering), 177 clinical signs and symptoms, 361

juvenile myelomonocytic leukemia, 484 digestion and microbial killing, 178–179 epidemiology, 361
laboratory data, 483, 483 engul ment, 178 etiology, 360
pathophysiology, 483 phagosomes, 178–179 laboratory data, 361
classi cation, 476, 482b site o injury, 177t whooping cough, 355

cytogenetics to prognosis, 477–478, 481 blood smear, 168 Nonmegaloblastic macrocytic anemias, 280–281,
etiology, 482 development, 165, 165 281b